|
Re: Potential Treatment For Advanced Post-Menopausal Breast Cancer Patients Resistant
Great news,
let's hope everolimus/afinitor gains approval from the FDA as soon as possible.
I'm also looking forward to see the results of the others two phase III trials, bolero 1 and bolero 3, which are looking at the combination of everolimus and herceptin for metastatic her2 pos breast cancer.
I was wondering, if the drug get the approval for estrogen receptor positive BC, this is limited to ER+/Her2- or it includes ER+/Her+ as well?
__________________
Son of Ha
She has been dignosed in February 2008 BC state IV, left breast multiple nodes size 5 cm, mets lungs and liver. Er+ Pr+ Her neu +++.
3/2008 - 10/2010 Herceptin + Aramidex NED
10/2010 recurrence lung met, pleural effusion, toracentesis
11/2010- Tyverb + Navalbine NED
08/2011 CA-15-3 = 90 scan
08/2011 Scan revealed reccurrence lung met, tiny metastasis on the pleura and pleural effusion.
4 pills tyverb, mytoxantrone once ever three weeks, and Aromasin.
Tykerb and taxol, sever allergic reaction
Tykerb taxotere
Herceptin, perjeta, gemcitabina
C- diff, bad diarrea
Halevan and tamoxifen, tm down from 1200 to 130
|